GB2238476A - Therapeutic aquatic animal and garlic products - Google Patents

Therapeutic aquatic animal and garlic products Download PDF

Info

Publication number
GB2238476A
GB2238476A GB8924968A GB8924968A GB2238476A GB 2238476 A GB2238476 A GB 2238476A GB 8924968 A GB8924968 A GB 8924968A GB 8924968 A GB8924968 A GB 8924968A GB 2238476 A GB2238476 A GB 2238476A
Authority
GB
United Kingdom
Prior art keywords
compositions
garlic
oils
therapeutic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB8924968A
Other versions
GB8924968D0 (en
Inventor
K T Lalvani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB8924968A priority Critical patent/GB2238476A/en
Publication of GB8924968D0 publication Critical patent/GB8924968D0/en
Publication of GB2238476A publication Critical patent/GB2238476A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962Allium, e.g. garden onion, leek, garlic or chives

Abstract

Products comprised from oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals and oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin are useful in lowering cholesterol and saturated fat levels in blood.

Description

COMPOSITIONS OF SOME THERAPEUTIC ADVANTAGE FROM FISH AND OTHER AQUATIC ANIMALS COMBINED WITH GARLIC INCLUDING OR EXCLUDING THE GARLIC ACTIVE PRINCIPLE ALLICIN This invention relates to a novel composition of therapeutic significance prepared from oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals and oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin.
Garlic has been used for thousands of years both as a culinary flavouring and as a preventative medicine. It appears to have a unique cardiovascular prophylactic effect.
It can significantly reduce blood fats and cholesterol, and seems to have an antithrombotic effect similar to that of aspirin.
The therapeutic value of oils derived from fish and other aquatic animals has only recently been appreciated. The are rich in long chain polyunsaturated fatty acids of the Omega3 series. The two most important Omega-3 acids are Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA).
These have been shown to have a hypotriglyceridaemic action and to a lesser extent a hypocholesterolaemic effect. When these fatty acids are present in the cell membranes and are metabolised to other compounds, the net results include antithrombotic and anti-inflammatory effects. Beneficial effects of these polyunsaturated fatty acids has also been noted in arthritis, cancer, diabetes, heart related diseases including high blood pressure and coronary heart disease, kidney related disorders and psoriasis.
Previously, garlic and aquatic animal preparations have always been presented seperately. Although these previously know individual compositions have given some therapeutic satisfaction, products combining the two would compliment each other and offer increased therapeutic advantage with improved patient compliance and convenience of a two-in-one therapy in a single dose.
It is therefore the principle object of this invention to provide products having therapeutic significance prepared from oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals and oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin. These products will be presented in hard or soft gelatin capsules and as a liquid for oral administration.
These combination products providing a convenient two-in-one dosage form would have combined desired therapeutic properties which would be more effective than the presently available seperately existing compositions.
Accordingly, the above object has been achieved by providing the two therapies in combinationtcomprising oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals with oils and/or extracts and/r powders derived from mature or immature garlic including or excluding the garlic active principle Allicin. The mixture is encapsulated in hard or soft gelatin capsules or in a liquidoral form with or without any additives, oils or derivatives from plant and animal sources e.g. Beta-sitosterol, a naturally occuring substance found in wheat germ knows for its anticholesterol properties.
It is believed that these combination preparations of oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals with oils and/or extracts and/or powders derived from mature or immature garlic including or excluding active principle Allicin has an added therapeutic advantage over previously known seperately existing compositions.
The following examples illustrate the invention and the advantages thereof. These examples are given by way of illustration only, and are not to be construed as limiting the invention either in scope or in spirit, as many modifications will be apparent from this disclosure to those skilled in the art.
Example i:- Garlic Oil & Cod Liver Oil in Hard or Soft Gelatin Capsules COMPONENT AMOUNT PER CAPSULE Garlic Oil 0.2 mg Cod Liver Oil or Fish Oil 999.8 mg The mixture is blended and then encapsulated in hard or soft gelatin capsules.
Example 2:- Garlic Oil & Cod Liver Oil in Hard or Soft Gelatin Capsules COMPONENT AMOUNT PER CAPSULE Garlic Oil i.O mg Cod Liver Oil or Fish Oil 99.0 mg The mixture is blended and then encapsulated in hard or soft gelatin capsules.
Example 3:- Salmon Oil and Garlic Oil COMPONENT AMOUNT PER TEASPOON (5 gm) Salmon Oil 4.995 gm Garlic Oil 0.005 gm The mixture is blended with or without malt extract and then bottled.
Example 4:- Marine Animal Oil and Garlic Powder in Hard or Soft P Gelatin Capsules COMPONENT AMOUNT PER CAPSULE Marine Animal Oil 0.75 gm Garlic Powder 0.25 gm The mixture is blended and then encapsulated in hard or soft gelatin capsules.
Example 5:- Marine Oil, Garlic Oil & Beta-sitosterol COMPONENT AMOUSTT PER CAPSULE Marine Oil 500 mg Garlic Oil 0.2 mg Beta-sitosterol 100 mg The mixture is blended and then bottled.
Products comprised from oils and/or derivatives and/or preparations derived from fish and /or other aquatic animals and oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin combined as disclosed herein will have physiological properties of therapeutic importance with respect to the treatment and/or prophylaxis of arthris, cancer, diabetes, heart related diseases including high blood pressure and coranory heart disease, kidney related disorders and psoriasis. Garlic and aquatic animal oil have a dual antithrombotic and anti-inflammatory effect. They lower blood cholesterol and fat levels which is physiologically important.

Claims (8)

  1. i. Compositions of therapeutic significance comprising of oils and/or derivatives and/or preparations derived from fish and/or other aquatic animals with oils and/or extracts and/or powders derived from mature or immature garlic including or excluding the garlic active principle Allicin.
  2. 2. Compositions as in Claim 1 in which Beta-sitosterol (a derivative from wheat embryo) may or may not be used.
  3. 3. Compositions as in Claim 1 wherein one or more plant based additives and their derivatives or oils may or may not be incorporated.
  4. 4. Compositions as in Claims 1,2 & 3 wherein the mixture is encapsulated in hard or soft gelatin capsules.
  5. 5. Compositions as in Claims 1,2 & 3 wherein the mixture is bottled as an oral liquid supplement with or without additives such as malt.
  6. 6. Compositions as in Claims 2,3 & 4 whereby the product may be used as a therapeutic food for the treatment and/or prophylaxis of arthritis, cancer, diabetes, heart related diseases-including high blood pressure and coronary heart disease, kidney related disorders and psoriasis.
  7. 7. Compositions as in Claims 2,3,4 & 5 whereby the product may be used as an antithrombotic and/or anti-inflammatory.
  8. 8. Compositions as in Claims 2,3,4 & 5 in which the product may be used to lower blood cholesterol and saturated fat levels.
GB8924968A 1989-11-04 1989-11-04 Therapeutic aquatic animal and garlic products Withdrawn GB2238476A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB8924968A GB2238476A (en) 1989-11-04 1989-11-04 Therapeutic aquatic animal and garlic products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8924968A GB2238476A (en) 1989-11-04 1989-11-04 Therapeutic aquatic animal and garlic products

Publications (2)

Publication Number Publication Date
GB8924968D0 GB8924968D0 (en) 1989-12-28
GB2238476A true GB2238476A (en) 1991-06-05

Family

ID=10665777

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8924968A Withdrawn GB2238476A (en) 1989-11-04 1989-11-04 Therapeutic aquatic animal and garlic products

Country Status (1)

Country Link
GB (1) GB2238476A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706307A1 (en) * 1993-06-18 1994-12-23 Pelletier Jacques Formula for the treatment of AIDS
FR2706771A1 (en) * 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
GB2304046A (en) * 1995-08-08 1997-03-12 Kofi Abaka Jackson Diabetes therapy
DE19701264A1 (en) * 1997-01-16 1998-07-23 Kief Lizenz Verwertungsgesells Remedies containing betasitosterol and / or phytosterol / betasitosteric mixtures
JP2012508791A (en) * 2008-11-14 2012-04-12 フラムローゼ,ボミ,ピー. Method for reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for the treatment of atherosclerosis
CN112535680A (en) * 2019-09-20 2021-03-23 新疆埃乐欣药业有限公司 Use of garlic-derived material for treating and/or preventing psoriasis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0232501A1 (en) * 1985-12-19 1987-08-19 Chimicasa Gmbh Pharmaceutical preparation for the treatment of lipid metabolism disorders (hyperlipoproteinemia)
EP0273407A2 (en) * 1986-12-30 1988-07-06 Roshdy Dr. Ismail Medicine for improving the specific properties of blood
DE3700785A1 (en) * 1987-01-13 1988-07-21 Sca Lohnherstellungs Ag Macerate, process for its preparation and its use as medicine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0232501A1 (en) * 1985-12-19 1987-08-19 Chimicasa Gmbh Pharmaceutical preparation for the treatment of lipid metabolism disorders (hyperlipoproteinemia)
EP0273407A2 (en) * 1986-12-30 1988-07-06 Roshdy Dr. Ismail Medicine for improving the specific properties of blood
DE3700785A1 (en) * 1987-01-13 1988-07-21 Sca Lohnherstellungs Ag Macerate, process for its preparation and its use as medicine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Martindale, The Extra Pharmacopoeia, (27th Edition) page 56 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706307A1 (en) * 1993-06-18 1994-12-23 Pelletier Jacques Formula for the treatment of AIDS
FR2706771A1 (en) * 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
GB2304046A (en) * 1995-08-08 1997-03-12 Kofi Abaka Jackson Diabetes therapy
GB2304046B (en) * 1995-08-08 1998-12-09 Kofi Abaka Jackson Diabetes therapy
DE19701264A1 (en) * 1997-01-16 1998-07-23 Kief Lizenz Verwertungsgesells Remedies containing betasitosterol and / or phytosterol / betasitosteric mixtures
WO1998031372A1 (en) * 1997-01-16 1998-07-23 Dr. Kief Lizenz Verwertungs Gesellschaft Mbh Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures
US6407085B1 (en) 1997-01-16 2002-06-18 Horst Kief Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures
JP2012508791A (en) * 2008-11-14 2012-04-12 フラムローゼ,ボミ,ピー. Method for reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for the treatment of atherosclerosis
CN112535680A (en) * 2019-09-20 2021-03-23 新疆埃乐欣药业有限公司 Use of garlic-derived material for treating and/or preventing psoriasis

Also Published As

Publication number Publication date
GB8924968D0 (en) 1989-12-28

Similar Documents

Publication Publication Date Title
US5562913A (en) Formulation for use in smokers
AU725308B2 (en) Anti-stress composition
US5656667A (en) Fatty acid composition
DE60123849T2 (en) OIL / GREASE COMPOSITION
JP3512196B2 (en) Food composition comprising a balance regulator for omega-6 and omega-3 unsaturated fatty acids
DE69935995T3 (en) POLYUNGATURATED FATTY ACIDS NUTRITIONAL SUPPLEMENT
JPH06128154A (en) Food composition
KR20030016306A (en) Therapeutic combinations of fatty acids
US20100280112A1 (en) Composition Enriched in Diglyceride with Conjugated Linoleic Acid
JPS6296422A (en) Manufacture of preventive or therapeutic composition for endometric proliferation and prevention or remedy therefor
GB2148713A (en) Pharmaceutical composition and food product comprising higher fatty acids
JPH05201924A (en) Fatty acid composition
DE3213744A1 (en) PHARMACEUTICAL AGENT
KR20040095263A (en) Body temperature elevating agents
JPH11286497A (en) Acylated derivative of glycosyl-l-ascorbic acid
JPH0458847A (en) Obesity-resistant fat and oil and obesity-resistant food
GB2238476A (en) Therapeutic aquatic animal and garlic products
US20100239660A1 (en) Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions
JPH0717515B2 (en) Composition for treating benign prostatic hypertrophy
JPH0825876B2 (en) Comedone therapeutic agent composition
JPH0336493B2 (en)
JP4234888B2 (en) Antihypertensive agent
JPS6216415A (en) Medicinal composition for treating syndrome before menses and therapy therefor
CN107372861B (en) Composition and application thereof in preparation of product for improving hyperlipidemia
JP3999914B2 (en) Oil composition

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)